Reports >
Life Sciences
>
Cancer Gene Therapy Market Report
Cancer Gene Therapy Market Report
First published: 11 October 2024 | Last updated: 25 May 2026 | Report Code: cancer-gene-therapy
Cancer Gene Therapy Market — USD 5.6 billion in 2023, Growing to USD 14.05B by 2033 at 9.3% CAGR
This report provides an in-depth analysis of the Cancer Gene Therapy market, covering key insights, market forecasts from 2023 to 2033, and comprehensive assessments of various regions and segments within the industry.
Key Takeaways
- Global market expands from $5.60 Billion in 2023 to $14.05 Billion by 2033 at a 9.3% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $1.61 Billion to $4.03 Billion between 2023 and 2033, reflecting sustained investment.
- Asia Pacific increases from $1.21 Billion to $3.03 Billion by 2033 amid escalating research activity.
- Leading companies include Novartis AG, Gilead Sciences, Inc., Spark Therapeutics, and Amgen, Inc.
Cancer Gene Therapy Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The report outlines the market trajectory for cancer-focused gene therapies, driven by technological advances, intensified clinical development and collaborations across biotech and research institutions. Market value is projected to grow from $5.60 Billion in 2023 to $14.05 Billion in 2033 at a 9.3% CAGR. North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. Europe and Asia Pacific also record notable increases in absolute value during the forecast period. Product and technology segmentation covers viral and non-viral platforms, gene editing tools and supporting materials. End-user breakdown notes hospitals, research institutes and pharmaceutical companies as primary adopters. The competitive landscape features Novartis AG, Gilead Sciences, Inc., Spark Therapeutics and Amgen, Inc., among others, emphasizing collaborations and pipeline advancement as key strategic moves. The report synthesizes primary expert interviews and secondary sources to present validated market narratives for stakeholders planning investment, partnership or development strategies.
Key Growth Drivers
- Advances in gene-editing and vector technologies enabling more targeted therapeutic approaches.
- Rising number of clinical programs focused on oncology that expand the development pipeline.
- Increased collaboration between biotech firms, academic centers and pharmaceutical companies accelerating translation.
- Growing demand for personalized treatments tailored to genetic profiles of tumors and patients.
- Improved regulatory pathways and greater investor interest supporting commercialization efforts.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $5.60 Billion |
| CAGR (2023-2033) | 9.3% |
| 2033 Market Size | $14.05 Billion |
| Top Companies | Novartis AG, Gilead Sciences, Inc., Spark Therapeutics, Amgen, Inc. |
| Published Date | 11 October 2024 |
| Last Modified Date | 25 May 2026 |
Cancer Gene Therapy Market Overview
Customize Cancer Gene Therapy Market Report market research report
- ✔ Get in-depth analysis of Cancer Gene Therapy market size, growth, and forecasts.
- ✔ Understand Cancer Gene Therapy's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Cancer Gene Therapy
What is the Market Size & CAGR of Cancer Gene Therapy Market Report market in 2023?
Cancer Gene Therapy Industry Analysis
Cancer Gene Therapy Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Cancer Gene Therapy Market Report Market Analysis Report by Region
Europe Cancer Gene Therapy Market Report:
Europe grows from $1.61 Billion in 2023 to $4.03 Billion in 2033. Regional drivers include strong research networks, supportive clinical infrastructures and collaboration between pharmaceutical companies and research centers advancing oncology gene therapy programs.Asia Pacific Cancer Gene Therapy Market Report:
Asia Pacific grows from $1.21 Billion in 2023 to $3.03 Billion in 2033. Growth reflects expanding research efforts, rising clinical activity and increasing investments in biopharmaceutical development across multiple markets in the region.North America Cancer Gene Therapy Market Report:
North America is largest regional market, rising from $1.93 Billion in 2023 to $4.84 Billion in 2033. This region benefits from concentrated R&D investment, extensive clinical trial activity and established biotech–academic partnerships that support commercial translation.South America Cancer Gene Therapy Market Report:
Latin America grows from $0.31 Billion in 2023 to $0.77 Billion in 2033. Local progress is supported by growing clinical research involvement and partnerships that aim to broaden access to novel oncology treatment approaches.Middle East & Africa Cancer Gene Therapy Market Report:
Middle East and Africa grows from $0.55 Billion in 2023 to $1.38 Billion in 2033. Drivers include escalating research collaborations and infrastructure development that enable participation in clinical development and localized deployment of advanced therapies.Tell us your focus area and get a customized research report.
Research Methodology
Cancer Gene Therapy Market Analysis By Product
The Cancer Gene Therapy market by product type encompasses various segments, with Plasmid DNA dominating the market size, projected to reach USD 8.93 billion by 2033 from USD 3.56 billion in 2023, capturing a substantial market share of 63.54%. Viral Vectors and Gene Editing Tools are also prominent, with estimated sizes of USD 3.18 billion and USD 1.95 billion, respectively, by 2033.
Cancer Gene Therapy Market Analysis By Therapeutic Area
By therapeutic area, Solid Tumors will retain the largest market allocation, increasing from USD 3.56 billion in 2023 to USD 8.93 billion by 2033, representing 63.54% market share. Hematological Cancers and Other Cancers will also contribute significantly to market growth.
Cancer Gene Therapy Market Analysis By Technology
The market is split between Viral-based and Non-viral Based Therapies, with Viral-based Therapies expected to yield USD 8.93 billion by 2033 from USD 3.56 billion in 2023. Additionally, gene silencing techniques are expected to grow, capturing a noteworthy share in future developments.
Cancer Gene Therapy Market Analysis By End User
Hospitals are projected to remain the leading end-user segment, with market size rising from USD 3.56 billion in 2023 to USD 8.93 billion by 2033, demonstrating the industry's focus on delivering care and treatments directly to patients within clinical settings.
Cancer Gene Therapy Market Analysis By Stage Of Development
In terms of development stage, Clinical Trials currently account for a substantial market size of USD 4.66 billion, expected to grow to USD 11.70 billion by 2033. This indicates the emphasis on advancing clinical research to transition therapies from lab to commercial markets.
Cancer Gene Therapy Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Cancer Gene Therapy Industry
Novartis AG:
Novartis is a leading global healthcare company focused on innovative medicines and has made significant advances in CAR-T cell therapy for hematological cancers.Gilead Sciences, Inc.:
Gilead specializes in antiviral drugs but has entered the gene therapy space, particularly with CAR-T therapeutics for treating various cancers.Spark Therapeutics:
This biotechnology firm focuses on developing therapies for genetic diseases, with gene therapy products aimed at rare genetic disorders and significant cancer treatments.Amgen, Inc.:
Amgen is a pioneer in biopharmaceutical manufacturing, continually investing in gene therapies, particularly for oncology.We're grateful to work with incredible clients.
FAQs
What is the market size of the Cancer Gene Therapy Market Report in 2023?
The market size in 2023 is $5.60 Billion, based on reported figures for that year and used as the reference point for the 2023 to 2033 forecast period.
How big will the market be by 2033?
By 2033 the market is projected to reach $14.05 Billion, representing the end value used in the forecast covering 2023 to 2033.
What is CAGR for the forecast period?
The compound annual growth rate for the 2023 to 2033 period is 9.3%, as stated for the overall market trajectory.
Is there a single fastest Growing region in the Cancer Gene Therapy Market Report market?
No single fastest-growing region is stated for the Cancer Gene Therapy Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies are identified as top players?
Top companies listed include Novartis AG, Gilead Sciences, Inc., Spark Therapeutics and Amgen, Inc., which are noted for active programs and strategic partnerships.
Who are the primary end users for these therapies?
Primary end users include hospitals, research institutes and pharmaceutical companies, which drive clinical adoption, research and development, and commercialization.
What drives market growth for cancer gene therapies?
Key growth factors include technological improvements, expanding clinical pipelines, collaborative development models and increasing emphasis on personalized oncology treatments.
How was the market data compiled?
Data were assembled via expert interviews, company reports and publications, followed by triangulation and internal validation to ensure consistency and reliability.